241 related articles for article (PubMed ID: 31546603)
21. [Effects of Panax notoginseng saponins on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in KK-Ay mice].
Yang CY; Xie ZG; Cheng WB; Jiang X; Chen ZH
Zhong Yao Cai; 2009 Oct; 32(10):1571-6. PubMed ID: 20112724
[TBL] [Abstract][Full Text] [Related]
22. Effects of salt supplementation in uninephrectomized KK-Ay mice: Examining the potential of a diabetic kidney disease model.
Sano R; Ryu K; Sasase T; Shinozaki Y; Teoh SH; Yamaguchi A; Uno K; Maekawa T; Ohta T; Miyajima K
J Toxicol Sci; 2023; 48(11):597-606. PubMed ID: 37914287
[TBL] [Abstract][Full Text] [Related]
23. Qiwei granules alleviates podocyte lesion in kidney of diabetic KK-Ay mice.
Zhou J; Sun W; Yoshitomi H; Li L; Qin L; Guo X; Wu L; Zhang Y; Wu X; Xu T; Gao M; Liu T
BMC Complement Altern Med; 2015 Mar; 15():97. PubMed ID: 25887645
[TBL] [Abstract][Full Text] [Related]
24. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
25. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Hirai T; Kimura T; Echizen H
Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
[TBL] [Abstract][Full Text] [Related]
26. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Shirakura T; Nomura J; Matsui C; Kobayashi T; Tamura M; Masuzaki H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):831-8. PubMed ID: 27198514
[TBL] [Abstract][Full Text] [Related]
27. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
28. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Kataoka H; Yang K; Rock KL
Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
[TBL] [Abstract][Full Text] [Related]
29. Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
Yisireyili M; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Shoaib Hamrah M; Nakayama T; Wu Cheng X; Matsushita T; Nakamura S; Niwa T; Murohara T; Takeshita K
Sci Rep; 2017 Apr; 7(1):1266. PubMed ID: 28455534
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant-induced improvement of glucose intolerance in type 2 diabetic KK-Ay mice through interleukin-1 and tumor necrosis factor-alpha.
Muto G; Satoh J; Muto Y; Takahashi K; Nakazawa T; Sagara M; Miyaguchi S; Fukuzawa M; Qiang X; Sakata Y; Takizawa Y; Li Y; Bando S; Housai T; Tamagawa A; Toyota T
Clin Immunol; 2000 Dec; 97(3):259-65. PubMed ID: 11112365
[TBL] [Abstract][Full Text] [Related]
31. Hyperuricemia in type 2 diabetic model KK-A
Adachi SI; Yoshizawa F; Yagasaki K
BMC Res Notes; 2017 Nov; 10(1):577. PubMed ID: 29115981
[TBL] [Abstract][Full Text] [Related]
32. 10-Hydroxy-2-decenoic acid, a natural product, improves hyperglycemia and insulin resistance in obese/diabetic KK-Ay mice, but does not prevent obesity.
Watadani R; Kotoh J; Sasaki D; Someya A; Matsumoto K; Maeda A
J Vet Med Sci; 2017 Sep; 79(9):1596-1602. PubMed ID: 28740028
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
34. [Study of effect of Humifuse Euphorbia Herb on alleviating insulin resistance in type 2 diabetic model KK-Ay mice].
Wang LL; Fu H; Li WW; Song FJ; Song YX; Yu Q; Liu GX; Wang XM
Zhongguo Zhong Yao Za Zhi; 2015 May; 40(10):1994-8. PubMed ID: 26390662
[TBL] [Abstract][Full Text] [Related]
35. The anti-diabetic activities, gut microbiota composition, the anti-inflammatory effects of Scutellaria-coptis herb couple against insulin resistance-model of diabetes involving the toll-like receptor 4 signaling pathway.
Zhang CH; Sheng JQ; Sarsaiya S; Shu FX; Liu TT; Tu XY; Ma GQ; Xu GL; Zheng HX; Zhou LF
J Ethnopharmacol; 2019 Jun; 237():202-214. PubMed ID: 30807814
[TBL] [Abstract][Full Text] [Related]
36. Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Kakimoto M; Fujii M; Sato I; Honma K; Nakayama H; Kirihara S; Fukuoka T; Ran S; Hirohata S; Kitamori K; Yamamoto S; Watanabe S
J Appl Biomed; 2023 Jun; 21(2):80-90. PubMed ID: 37376883
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients.
Hirai T; Itoh T; Kimura T; Echizen H
Br J Clin Pharmacol; 2018 Oct; 84(10):2260-2269. PubMed ID: 29876951
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice.
Takahashi K; Mizukami H; Osonoi S; Ogasawara S; Hara Y; Kudoh K; Takeuchi Y; Sasaki T; Daimon M; Yagihashi S
Neurobiol Dis; 2021 Jul; 155():105392. PubMed ID: 34000416
[TBL] [Abstract][Full Text] [Related]
39. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Sezai A; Obata K; Abe K; Kanno S; Sekino H
Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Fahmi AN; Shehatou GS; Shebl AM; Salem HA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
